FDA Grants Priority Review to Savara's MOLBREEVI: What's Changed

Savara Inc.'s (SVRA) stock has fallen 8.0% after the FDA granted Priority Review to MOLBREEVI, a treatment for autoimmune pulmonary alveolar proteinosis. The FDA has accepted the Biologics License Application for MOLBREEVI and set a PDUFA action date of August 22, 2026. The company's investment narrative now focuses on MOLBREEVI's potential as a rare disease franchise and the executional risks involved. The recent pullback suggests the market is reassessing the balance of promise and execution risk.